Titan Biotech Ltd (TITANBIO) is currently trading at 437.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Titan Biotech Ltd. specializes in manufacturing biological peptones, extracts, and dehydrated culture media to support the growth of microorganisms crucial for diagnostics, vaccines, and pharmaceuticals. The company uses animal and vegetable components to convert them into peptones, which become core sources for culture media, utilized broadly in healthcare and microbiological research. Historically, Titan Biotech has expanded its product line to include gamma-irradiated culture media, lab chemicals, and agaroses, which serve research institutes and commercial applications. In 2009-10, Titan Biotech developed Amino acid Chelates and harmonized media, marking significant strides in enhancing its product offerings. The company contributes meaningfully to pharmaceutical and microbiology industries by supplying key materials for microbial growth and testing requirements.

Over the past 52 weeks, Titan Biotech Ltd has traded between a low of ₹143.00 and a high of ₹555.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Titan Biotech Ltd has a market capitalization of approximately 1,734.96. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Titan Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.42 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,734.96 Cr, Titan Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Titan Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Titan Biotech Ltd is 56.42. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.